Drug intelligence / Profile preview

Nozoil

Development stage: Unknown
Lead developer: RIS Products
Modality: Small Molecules
Administration: Intranasal

Overview

Nozoil is a nasal spray developed and manufactured by Trommsdorff GmbH & Co. KG, consisting of 100% pure sesame oil enriched with vitamin E. It is classified as an approved medical device indicated for the treatment of symptomatic nasal conditions such as dry nasal mucosa (rhinitis sicca), nasal crusting, and irritation caused by dry air or environmental factors. The product functions through a physical mechanism of action, providing lubrication and moisturizing the nasal epithelium to restore the natural mucosal barrier. Nozoil is preservative-free and does not contain pharmaceutical active ingredients like corticosteroids or decongestants, preventing rebound effects and making it suitable for long-term daily use.

Brand names: NozoilRhinaris Nozoil
Other names: sesame oilNozoil nasal spray

Beyond the preview

Go deeper on Nozoil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nozoil.

Explore the full profile